Zydus Cadila Leading Global Race For Humira Biosimilar?
This article was originally published in PharmAsia News
Executive Summary
India’s Zydus Cadila stands a bright chance of leading the heated global chase to launch a biosimilar version of adalimumab, AbbVie’s blockbuster Humira, which is also the top-selling drug in the world notching close to $11 billion last year.
You may also be interested in...
With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim
MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.